Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine for Prevention of Cirrhosis Complications in Children
NCT05287100Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of midodrine in Cirrhosis (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Incidence of complications (Acute kidney injury, New onset ascites or increase in grade of ascites, Spontaneous bacterial peritonitis, Hyponatremia, Hepatic encephalopathy) at 6 months. Started Jan 2022; status: completed.
02
Drugs
midodrine
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NCT05287100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287100.